While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions
Reduces Fine Lines and Wrinkles GHK-Cu helps reduce the depth and visibility of fine lines by increasing glycosaminoglycans (such as hyaluronic acid), which plumps the skin and restores volume
The reality check: longer trials did not justify a commercial obesity drug The same obesity-pharmacotherapy review literature notes that development was terminated after a longer trial failed to demonstrate sufficiently meaningful weight loss to be commercially viable
C.AthanasiouK
B12 injections are used to treat pernicious anemia, but high doses of vitamin B12 can cause serious side effects, including: blood clots, heart failure, low potassium, and fluid buildup in the lungs
I joined a membership program guided by Cree, who walked me through every step and made me feel instantly at home
